The babel of drugs: On the consequences of evidential pluralism in pharmaceutical regulation and regulatory data journeys
dc.contributor.author | Tempini, N | |
dc.contributor.author | Teira, D | |
dc.date.accessioned | 2021-02-15T08:22:29Z | |
dc.date.issued | 2020-06-30 | |
dc.description.abstract | Throughout the last century, pharmaceutical regulators all over the world have used various methods to test medical treatments. From 1962 until 2016, the Randomized Clinical Trial (RCT) was the reference test for most regulatory agencies. Today, the standards are about to change, and in this chapter we draw on the idea of the data journey to illuminate the trade-offs involved. The 21st Century Cures Act (21CCA) allows for the use of Electronic Health Records (EHRs) for the assessment of different treatment indications for already approved drugs. This might arguably shorten the testing period, bringing treatments to patients faster. Yet, EHR are not generated for testing purposes and no amount of standardization and curation can fully make up for their potential flaws as evidence of safety and efficacy. The more noise in the data, the more mistakes regulators are likely to make in granting market access to new drugs. In this paper we will discuss the different dimensions of this journey: the different sources and levels of curation involved, the speed at which they can travel, and the level of risk of regulatory error involved as compared with the RCT standard. We are going to defend that what counts as evidence, at the end of the journey, depends on the risk definition and threshold regulators work with. | en_GB |
dc.description.sponsorship | European Research Council (ERC) | en_GB |
dc.description.sponsorship | Engineering and Physical Sciences Research Council (EPSRC) | en_GB |
dc.identifier.citation | In: Data Journeys in the Sciences, edited by Sabina Leonelli and Niccolò Tempini, pp. 207 - 225 | en_GB |
dc.identifier.doi | 10.1007/978-3-030-37177-7_11 | |
dc.identifier.grantnumber | 335925 | en_GB |
dc.identifier.grantnumber | EP/N510129/1 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/124727 | |
dc.language.iso | en | en_GB |
dc.publisher | Springer | en_GB |
dc.rights | © The Author(s) 2020. Open Access. This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. | en_GB |
dc.title | The babel of drugs: On the consequences of evidential pluralism in pharmaceutical regulation and regulatory data journeys | en_GB |
dc.type | Book chapter | en_GB |
dc.date.available | 2021-02-15T08:22:29Z | |
dc.identifier.isbn | 9783030371760 | |
dc.relation.isPartOf | Data Journeys in the Sciences | en_GB |
dc.description | This is the final version. Available on open access from Springer via the DOI in this record | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_GB |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2020-06-30 | |
rioxxterms.type | Book chapter | en_GB |
refterms.dateFCD | 2021-02-15T08:19:58Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2021-02-15T08:22:32Z |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © The Author(s) 2020. Open Access.
This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.